Drug Trial Radar · NCT03547973
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
502
Actual
Start
Aug 13, 2018
Primary completion
Apr 2030
Study completion Apr 2030
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jun 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Conditions
- Metastatic Urothelial Cancer
Interventions
Sacituzumab Govitecan-hziyDrug
Administered intravenously.
PembrolizumabDrug
Administered per package insert
CisplatinDrug
Administered per package insert
AvelumabDrug
Administered per package insert
ZimberelimabDrug
Administered intravenously
CarboplatinDrug
Administered per package insert
GemcitabineDrug
Administered per package insert
DomvanalimabDrug
Administered intravenously
Enfortumab VedotinDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) Based on Central Review by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Criteria (Cohorts 1 to 4 and 6)Time frame: Up to Survival Follow-up Visit (maximum of 2 years after Safety Follow-up Visit (30 days after last dose date))
- Progression free survival (PFS) Based on Central Review by RECIST 1.1 criteria (Cohort 5)Time frame: Up to Survival Follow-up Visit (maximum of 2 years after Safety Follow-up Visit (30 days after last dose date))
- ORR Based on Investigator Review by RECIST 1.1 Criteria (Cohort 7)Time frame: Up to Survival Follow-up Visit (maximum of 2 years after Safety Follow-up Visit (30 days after last dose date))
- Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs) (Cohort 7)Time frame: First dose date up to last dose date plus 30 days (approximately 3 years)
- Percentage of Participants Experiencing any Clinically Significant Laboratory Abnormalities (Cohort 7)Time frame: First dose date up to last dose date plus 30 days (approximately 3 years)
Locations
128 sites in 9 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center-North Campus
Tucson, Arizona
University of California San Francisco
San Francisco, California
Rocky Mountain Cancer Centers
Littleton, Colorado
Smilow Cancer Hospital at Yale-New Haven
New Haven, Connecticut
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Woodlands Medical Specialists, PA
Pensacola, Florida
Moffitt Cancer Center
Tampa, Florida
Winship Cancer Institute, Emory University
Atlanta, Georgia
University of Illinois Cancer Center
Chicago, Illinois
University of Chicago Medical Center
Chicago, Illinois
Southern Illinois University School of Medicine, Simmons Cancer Institute
Springfield, Illinois
Norton Cancer Institute, Downtown
Louisville, Kentucky
University of Michigan
Ann Arbor, Michigan
Karmanos Cancer Institute
Detroit, Michigan
Precision Cancer Research / New Mexico Oncology & Hematology Consultants
Albuquerque, New Mexico
Roswell Park Cancer Institute
Buffalo, New York
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York
Drug Shipping Address: New York-Presbyterian Hospital
New York, New York
Stony Brook Cancer Center
Stony Brook, New York
St. Luke's Hosptial - Bethlehem Campus
Easton, Pennsylvania
Medical University of Southern Carolina
Charleston, South Carolina
Thompson Oncology Group - Knoxville West
Knoxville, Tennessee
Henry-Joyce Cancer Clinic
Nashville, Tennessee
Houston Methodist Hospital, Houston Methodist Cancer Center
Houston, Texas
Mays Cancer Center
San Antonio, Texas
University of Utah - Huntsman Cancer Hospital (IP Shipping Address)
Salt Lake City, Utah
Virginia Oncology Associates
Hampton, Virginia
Oncology Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Roanoke, Virginia
Seattle Cancer Care Alliance
Seattle, Washington
University of Wisconsin Clinical Science Center
Madison, Wisconsin
Centre Hospitalier Regional Universitaire (CHRU) de Besancon, Hopital Jean Minjoz
Besançon, France
Hopital Saint Andre (CHU de Bordeaux)
Bordeaux, France
Centre Hospitalier Regional Universitaire Brest
Brest, France
Centre Jean Perrin
Clermont-Ferrand, France
Centre Hospitalier Departmental (CHD) Vendee
La Roche-sur-Yon, France
Centre Oscar Lambret
Lille, France
Centre Leon Berard
Lyon, France
Institut Paoli Calmettes
Marseille, France
Centre Antoine Lacassagne
Nice, France
Centre Hospitalier Universitaire De Nimes - Hopital Universitaire Caremeau
Nîmes, France
Showing 40 of 128 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.